Related Experiment Video
Updated: Jun 5, 2026
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
[New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334]
1Clinical Development Planning I-II, Ono Pharmaceutical Company Limited.
Abstract:
ONO-5334, an orally-administered low-molecular compound, is a selective synthetic inhibitor of cathepsin K which is specifically expressed in osteoclasts and has a critical role in bone-collagen degradation. ONO-5334 is being developed by Ono Pharmaceutical Co., Ltd. as a possible therapeutic agent for osteoporosis. ONO-5334 has been shown to prevent the decrease in bone mineral density (BMD) in the ovariectomized cynomolgus monkey osteoporosis model. In a 12-month clinical study with postmenopausal osteopenia or osteoporosis, ONO-5334 showed a significant increase in BMD compared with placebo and a similar magnitude of suppression on bone resorption compared with the current well known anti-resorptive agents, bisphosphonates, but with little or no suppression on bone formation. There were no clinically relevant safety concerns identified in this study. Whether this mechanism of action may result in more potent anti-fracture efficacy accompanied by better bone quality in long term use of ONO-5334 is of significant interest.
Insights
ONO-5334, a cathepsin K inhibitor, effectively increased bone mineral density in osteoporosis patients. This new osteoporosis drug shows promise with good safety and bone resorption suppression without hindering bone formation.
Area of Science:
- Pharmacology
- Bone Biology
- Drug Development
Context:
- Osteoporosis is a significant health concern characterized by decreased bone mineral density and increased fracture risk.
- Cathepsin K is a key enzyme in osteoclasts, crucial for bone collagen degradation.
- Current osteoporosis treatments primarily focus on anti-resorptive mechanisms.
Purpose:
- To evaluate the efficacy and safety of ONO-5334, a selective cathepsin K inhibitor, for osteoporosis treatment.
- To assess ONO-5334's effect on bone mineral density and bone turnover markers in postmenopausal women.
- To compare ONO-5334's bone resorption inhibition with bisphosphonates and its impact on bone formation.
Summary:
- ONO-5334, an oral cathepsin K inhibitor, demonstrated a significant increase in bone mineral density (BMD) in a 12-month clinical study involving postmenopausal women with osteopenia or osteoporosis.
- The compound effectively suppressed bone resorption, comparable to bisphosphonates, while exhibiting minimal impact on bone formation.
- Preclinical studies in an ovariectomized monkey model also showed ONO-5334 prevented bone mineral density loss.
Impact:
- ONO-5334 represents a potential new therapeutic agent for osteoporosis with a favorable efficacy and safety profile.
- Its selective inhibition of cathepsin K may offer advantages over existing treatments by preserving bone quality.
- Further long-term studies are warranted to confirm its anti-fracture efficacy and long-term bone quality benefits.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...